Current Report Filing (8-k)

Date : 06/11/2019 @ 4:16PM
Source : Edgar (US Regulatory)
Stock : Genprex Inc (GNPX)
Quote : 0.5254  0.0 (0.00%) @ 9:00AM
Genprex share price Chart

Current Report Filing (8-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549  

   

 


 

FORM 8-K  

    


 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

June 5 , 201 9

Date of report (Date of earliest event reported)

 

GENPREX, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

001-38244

90 - 0772347

(State or other jurisdiction of

incorporation or organization)

(Commission File Number)

(I.R.S. Employer

Identification Number)

 

 

 

1 6 01   Trinity Street , Suite 3.322 , Austin, TX

 

787 12

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (512) 537-7997

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

GNPX

 

The Nasdaq Capital Market

 

 

 

 

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

(b) 

 

As disclosed in this Current Report on Form 8-K filed by Genprex, Inc. (the “Company”), effective June 10, 2019, John N. Bonfiglio, PhD resigned from the Company’s board of directors (the “Board”). Dr. Bonfiglio’s resignation as a member of the Board also constituted his resignation as a member of the audit committee of the board (the “Audit Committee”). As a result of Dr. Bonfiglio’s resignation, the composition of the Audit Committee was reduced from three members to two members.

 

Following the resignation of Dr. Bonfiglio as a director of the Company and member of the Audit Committee, the Company was no longer in compliance with Nasdaq Listing Rule 5605(c)(2)(A), which requires that the audit committee of a listed company be composed of at least three independent directors.

 

On June 10, 2019, the Company notified The Nasdaq Stock Market, Inc. that it was not in compliance with Nasdaq Listing Rule 5605(c)(2)(A) as a result of the vacancy on the Board caused by Dr. Bonfiglio resigning from the Board and the Audit Committee effective June 10, 2019.

 

Nasdaq Listing Rule 5605(c)(2)(A) requires the Audit Committee to have at least three independent members (as defined by Nasdaq Listing Rule 5605(a)(2) and Rule 10A-3(b)(1) under the Securities Exchange Act of 1934), at least one of whom is an audit committee financial expert.  Dr. Bonfiglio was one of the three independent directors on the Audit Committee. David E. Friedman, an independent member of the Board and the Chair of the Audit Committee, is the Audit Committee financial expert for purposes of, and in accordance with, Nasdaq and Securities and Exchange Commission rules.

 

The Nasdaq Listing Rules provide for a cure period during which the Company may regain compliance with Nasdaq Listing Rule 5605(c)(2)(A). Under Nasdaq Listing Rule 5605(c)(4), the Company shall have until the earlier of its next annual meeting of stockholders or one year from the occurrence of the event that caused the failure to comply with Nasdaq Listing Rule 5605(c)(2)(A); provided, however, that if the next annual meeting of stockholders occurs no later than 180 days following the event that caused the vacancy, the Company shall instead have 180 days from such event to regain compliance.

 

The Company intends to fill the vacancy on the Board and the Audit Committee and to cure all related non-compliance within the cure period provided under Nasdaq Listing Rule 5605(c)(4).

 

 

  Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(a)

 

On June 5, 2019, John N. Bonfiglio, PhD, notified the Company of his decision to resign as a member of the Board, effective as of June 10, 2019, the date of the Company’s 2019 Annual Meeting of Stockholders. At the time of Dr. Bonfiglio’s resignation, he was an independent director and member of the Audit Committee, the Compensation Committee of the Board and the Nominating and Corporate Governance Committee of the Board. Dr. Bonfiglio’s resignation as a member of the Board also constitutes his resignation as a member of each of these committees. Dr. Bonfiglio’s resignation was not because of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

 

The Nominating and Corporate Governance Committee of the Board has initiated a search to identify qualified candidates to replace Dr. Bonfiglio as a director of the Company and member of the Audit Committee.

 

 

 

 

Item 5 .0 7 : Submission of Matters to a Vote of Security Holders .

 

On June 10, 2019, the Company held its 2019 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 25, 2019, the record date for the Annual Meeting, 15,531,765 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.

 

A total of 9,856,093 shares of the Company’s common stock were present at the meeting in person or by proxy, which represents approximately 63.46% of the shares of common stock outstanding as of the record date for the Annual Meeting.

 

Proposal 1 . Election of Director.

 

The Company’s stockholders elected the person listed below as a Class II Director, to serve until the Company’s 2022 Annual Meeting of Stockholders and until his successor is duly elected and qualified. The final voting results are as follows:

 

 

Name

  

Votes For

  

Votes Withheld

  

Broker Non-Votes

Robert W. Pearson

  

6,297,799

  

49,456

  

3,508,838

 

Proposal 2 . Ratification of the Selection of Independent Registered Public Accounting Firm.

 

The Company’s stockholders ratified the selection of Daszkal Bolton LLP by the Audit Committee of the Company’s Board of Directors as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019. The final voting results are as follows:

 

 

Votes For

  

Votes Against

  

Abstention

  

Broker Non-Votes

9,490,443

  

272,695

  

92,955

  

0

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

GENPREX, INC.

 

 

 

 

 

Date: June 11, 2019

By:

/s/ Ryan Confer

 

 

 

Ryan Confer

 

 

 

Chief Financial Officer

(Principal Financial Officer)

 

 

Genprex (NASDAQ:GNPX)
Historical Stock Chart

1 Year : From Oct 2018 to Oct 2019

Click Here for more Genprex Charts.

Genprex (NASDAQ:GNPX)
Intraday Stock Chart

Today : Tuesday 22 October 2019

Click Here for more Genprex Charts.

Latest GNPX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191022 08:41:49